Literature DB >> 11122763

Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events.

J B Muhlestein1.   

Abstract

Evidence is mounting that infectious agents might be involved in atherosclerosis. Therefore, antibiotic therapy might be helpful in its prevention. Early pilot therapeutic trials have targeted Chlamydia pneumoniae because it has the most evidence associating it with atherosclerosis. Small, randomized pilot trials that test the effect of macrolide therapy on future clinical events in patients with coronary artery disease have already shown promising but mixed results. Large clinical trials are presently underway that should provide more definitive information regarding the use of antibiotics in coronary artery disease. Until the results of these studies are available, it is not recommended that antibiotic therapy be routinely utilized for the treatment or prevention of complications of atherosclerosis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122763     DOI： 10.1007/s11883-000-0068-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  34 in total

Review 1.  New insights into the pathogenesis and prevention of acute coronary syndromes.

Authors:  P K Shah
Journal:  Am J Cardiol       Date:  1997-06-26       Impact factor: 2.778

2.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.

Authors:  J B Muhlestein; J L Anderson; J F Carlquist; K Salunkhe; B D Horne; R R Pearson; T J Bunch; A Allen; S Trehan; C Nielson
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

4.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.

Authors:  J L Anderson; J B Muhlestein; J Carlquist; A Allen; S Trehan; C Nielson; S Hall; J Brady; M Egger; B Horne; T Lim
Journal:  Circulation       Date:  1999-03-30       Impact factor: 29.690

5.  Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group.

Authors:  J A Ramirez
Journal:  Ann Intern Med       Date:  1996-12-15       Impact factor: 25.391

6.  Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain.

Authors:  C C Kuo; A M Gown; E P Benditt; J T Grayston
Journal:  Arterioscler Thromb       Date:  1993-10

Review 7.  Animal models for Chlamydia pneumoniae infection.

Authors:  P Saikku; K Laitinen; M Leinonen
Journal:  Atherosclerosis       Date:  1998-10       Impact factor: 5.162

Review 8.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.

Authors:  W L Beatty; R P Morrison; G I Byrne
Journal:  Microbiol Rev       Date:  1994-12

9.  Association between dental health and acute myocardial infarction.

Authors:  K J Mattila; M S Nieminen; V V Valtonen; V P Rasi; Y A Kesäniemi; S L Syrjälä; P S Jungell; M Isoluoma; K Hietaniemi; M J Jokinen
Journal:  BMJ       Date:  1989-03-25

10.  Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland.

Authors:  H Miettinen; S Lehto; P Saikku; S M Haffner; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Eur Heart J       Date:  1996-05       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.